This pleotropic effect of sitagliptin may explain the reduction in postprandial lipemia seen in clinical trials of this agent and may provide metabolic benefits beyond glucose lowering (Diabetes)
Diabetes News
Category: Medication
Lilly’s Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes
https://investor.lilly.com/releasedetail.cfm?ReleaseID=828056
Janssen announce the launch of INVOKANA® (canagliflozin) in the UK
UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes1 – press release (Janssen)
GLP-1 receptor agonists
Why is once weekly inferior to once daily? (The Lancet Diabetes & Endocrinology)
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
A definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated (Diabetes Research and Clinical Practice)
Lixisenatide Resensitizes The Insulin-Secretory Response To Intravenous Glucose Challenge T2D
Lixisenatide thereby accelerates glucose disposal to nearly physiological intensity, and does not impair counter-regulation to low glucose levels by glucagon (Diabetes, Obesity and Metabolism)
Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR
In this 4-week study in patients with T2DM inadequately controlled with metformin monotherapy, saxagliptin added to metformin XR demonstrated a trend for improvement in measures of daily glycemic control, with fewer gastrointestinal adverse events, compared with uptitrated metformin (Diabetes Therapy)
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
GLP-1RAs provide superior glycaemic control and weight loss vs. DPP-4 inhibitors in patients with T2D. DPP-4 inhibitors may sometimes be preferred to a GLP-1RA if weight is not a concern, oral administration is a desirable feature or when a GLP-1RA cannot be tolerated (International Journal of Clinical Practice)
A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus
BIAsp 30 added to OAD therapy results in a better glycaemic control as compared with IGlar in T2DM patients. BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes (International Journal of Clinical Practice)
Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
It is possible to achieve similar glycemic control with once-daily injection and lower doses of insulin degludec in patients with T1DM who have been treated with insulin glargine or detemir (Diabetes Therapy)
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in 2D
Once-daily lixisenatide significantly improved glycemic control, with a pronounced postprandial effect, without significant increase in symptomatic/severe hypoglycemia risk and with weight loss over 24 weeks (Diabetes and Its Complications)
Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years’ duration
Even after long duration of diabetes, addition of glimepiride to insulin and metformin can be effective in lowering HbA1c and/or reducing the need for exogenous insulin (Diabetes Research and Clinical Practice)
Statin use and lower extremity amputation risk in nonelderly diabetic patients
This is the first study to report a significant association between statin use and diminished amputation risk among patients with diabetes (Journal of Vascular Surgery)
Xigduo™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes
AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (AstraZeneca)
The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: A retrospective cohort study
Withdrawal of rosiglitazone was associated with worsening glucose control and subsequent intensification of treatment regimen (Diabetes and Its Complications)
Old and New Basal Insulin Formulations: Understanding Pharmacodynamics is Still Relevant in Clinical Practice
Despite (in fact because of) the widespread use of insulin analogues it remains critical to analyse the pharmacodynamics (PD) of basal insulin formulations appropriately to interpret the results of clinical trials correctly. Importantly, these data may help physicians in tailoring insulin therapy to patients’ individual needs and, additionally, when clinical evidence is not available, to optimise insulin treatment (Diabetes, Obesity and Metabolism)
Chinese Herbal Medicine Tianqi Reduces Progression From Impaired Glucose Tolerance to Diabetes
Treatment with a Tianqi capsule for 12 months significantly decreased the incidence of T2DM in subjects with IGT, and this herbal drug was safe to use (Journal of Clinical Endocrinology & Metabolism)
Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
Our data suggest that treatment with saxagliptin for 6 weeks normalizes retinal capillary flow and improves central hemodynamics in type-2 diabetes (Cardiovascular Diabetology)
Effect of alogliptin and pioglitazone combination therapy on beta-cell function
Short-term treatment with ALO/PIO or ALO improved glycemic control in well-controlled T2DM patients, but only combined ALO/PIO improved beta-cell function. These data support that initial combination therapy with a DPP-4 inhibitor and TZD to address multiple core defects in T2DM may be a sensible approach (European Journal of Endocrinology)
Is Statin-induced Diabetes Clinically Relevant? A Comprehensive Review of the Literature
Despite the fact that higher statin doses are more likely to lead to new-onset diabetes, for every case of diabetes caused, there are approximately three cardiovascular events reduced with high dose vs. moderate dose statin therapy. Overall, the small risk of developing type 2 diabetes with statin therapy is far outweighed by the potential of statins to decrease cardiac events (Diabetes, Obesity and Metabolism)
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 56
- Next Page »